MoonLake Immunotherapeutics Class A (MLTX)
NASDAQ: MLTXHealthcareBiotechnologyUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
MLTX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $916.60M
- EPS (TTM)
- -$3.77
- Dividend yield
- None
- 52-week range
- 8.80 – 23.29
- Day range
- 10.71 – 11.29
- Volume / Avg
- 1.40M / 1.44M
- Beta
- —
- Shares outstanding
- 85.11M
- Next earnings
- Nov 4, 2026
52-week range
MLTX stock today
MoonLake Immunotherapeutics (MLTX) closed at $10.77 on Oct 7, down 1.64% (-$0.18), versus the S&P 500's 0.22% decline. Shares are 53.8% below their 52-week high of $23.29, set on Jun 22, 2026 and 22.4% above the 52-week low of $8.80, near the bottom of the past year's range. MLTX is down 18.3% year to date, underperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 16.1%.
MoonLake Immunotherapeutics has posted a net loss over the last twelve months (EPS of -$3.77), so its P/E ratio is not meaningful. MoonLake Immunotherapeutics's next earnings report is expected on Nov 4, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About MoonLake Immunotherapeutics
Company profileMoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis. The company was founded in 2021 and is headquartered in Zug, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dr. Jorge Santos da Silva Ph.D.
- Headquarters
- Zug
- Employees
- 130
- IPO year
- 2020
- Website
- moonlaketx.com
Analyst forecast
ForecastConsensus (15 analysts)
buy
Avg. price target
$28.54+165.00%
- Strong buy 1
- Buy 10
- Hold 2
- Sell 2
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 4, 2026
- EPS estimate
- $-0.77
MoonLake Immunotherapeutics peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ANROAlto Neuroscience Inc. | 23.52 | -0.72% | $922.97M | vs MLTX |
| KURAKura Oncology Inc. | 10.67 | +1.33% | $949.21M | vs MLTX |
| ANLAdlai Nortye Group Ltd. ADR | 14.05 | -2.84% | $904.79M | vs MLTX |
| SPTXSeaport Therapeutics Inc. | 17.93 | +3.22% | $959.80M | vs MLTX |
| CGEMCullinan Therapeutics Inc. | 15.63 | -3.82% | $960.59M | vs MLTX |
| RIGLRigel Pharmaceuticals Inc. | 47.99 | +4.08% | $896.45M | vs MLTX |
| ALMSAlumis Inc. | 6.77 | -2.31% | $876.28M | vs MLTX |
| JBIOJade Biosciences Inc. | 13.77 | +2.68% | $875.74M | vs MLTX |
Indexes, lists and sector
Appears in lists
MoonLake Immunotherapeutics stock FAQ
What is MoonLake Immunotherapeutics's stock price today?
MLTX last traded at $10.77 as of Oct 7, 4:00 PM EDT, down 1.64% on the day. Prices are delayed at least 15 minutes.
When is MoonLake Immunotherapeutics's next earnings date?
MoonLake Immunotherapeutics is expected to report earnings on Wednesday, November 4, 2026. Analysts expect EPS of $-0.77.
Who is MoonLake Immunotherapeutics's CEO?
Dr. Jorge Santos da Silva Ph.D. is the chief executive officer of MoonLake Immunotherapeutics Class A, which has about 130 employees.
What is the MLTX 52-week high?
The 52-week high for MLTX is $23.29 and the 52-week low is $8.80. The stock is currently 53.8% below its high.